UNITED STATES SECURITIES AND EXCHANGE COMMISSION December 21, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

GW Pharmaceuticals plc

File No. 001-35892 - CF#35782

GW Pharmaceuticals plc submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on December 4, 2017.

Based on representations by GW Pharmaceuticals plc that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 4.81	through December 4, 2027
Exhibit 4.82	through December 4, 2027
Exhibit 4.83	through December 4, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary